【藥品訊息】 必爾生口服液 仿單

氣喘或慢性阻塞性肺病 Allergic condition,Asthma,Collagen disease,Disorder of endocrine system,Disorder of eye,Disorder of gastrointestinal tract,Disorder of hematopoietic structure,Disorder of respiratory system,Disorder of skin,Exacerbation of multiple sclerosis (Acute),Hodgkin's disease,Inflammatory disorder of musculoskeletal system,Neoplastic disease,Nephrotic syndrome, Idiopathic or due to lupus erythematosus,Non-Hodgkin's lymphoma,Rheumatoid arthritis,Hearing loss.

Prednisolone is a synthetic adrenocorticosteroid that mainly exerts glucocorticoid effects like promotion of gluconeogenesis, increased deposition of glycogen in the liver, inhibition of utilization of glucose, anti-insulin activity, increased catabolism of protein, increased lipolysis, stimulation of fat synthesis and storage, and increased urate and calcium excretion. Prednisolone reduces eosinophils and lymphocytes production, stimulates erythropoiesis and polymorphonuclear leukocytes production and inhibits inflammatory processes and wound healing. Prednisolone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotrophin may lead to suppression of endogenous corticosteroids.

Duration：18-36 hr;
Absorption：rapidly and well absorbed
Plasma protein binding：70-90%
Metabolism：liver
Eliminated half-life : 2-4 hr

Systemic fungal infections

C(FDA),A(AUS)

AAP: Maternal medication usually compatible with breastfeeding.
WHO: Compatible with breastfeeding.
Micromedex: Infant risk is minimal.

Cardiovascular: Cardiac failure, cardiomyopathy, edema, facial edema, hypertension
Central nervous system: Headache, insomnia, malaise, myasthenia, nervousness, pseudotumor cerebri, psychological disorder, seizure, vertigo
Dermatologic: Diaphoresis, facial erythema, skin atrophy, suppression of skin test reaction, urticaria
Endocrine & metabolic: Cushing's syndrome, diabetes mellitus, growth suppression, hirsutism, HPA-axis suppression, hyperglycemia, hypernatremia, hypokalemia, hypokalemic alkalosis, menstrual disease, negative nitrogen balance, weight gain
Gastrointestinal: Abdominal distention, carbohydrate intolerance, dyspepsia, increased appetite, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis
Hematologic & oncologic: Bruise, petechia
Hepatic: Increased liver enzymes (usually reversible)
Neuromuscular & skeletal: Amyotrophy, arthralgia, aseptic necrosis of bones (humeral/femoral heads), bone fracture, rupture of tendon, weakness
Ophthalmic: Cataract, exophthalmos, eye irritation, eyelid edema, glaucoma, increased intraocular pressure
Respiratory: Epistaxis
Miscellaneous: Wound healing impairment
Venous thrombosis

Alcoholic hepatitis, Severe disease：40 mg/day orally for 4 weeks and then taper over 2 to 4 weeks or discontinue, based on clinical situation
Allergic condition：5 to 60 mg/day ORALLY
Asthma：40 to 80 mg/day ORALLY in 1 or 2 divided doses
Collagen disease,Disorder of endocrine system,Disorder of eye,Disorder of gastrointestinal tract,Disorder of hematopoietic structure,Disorder of respiratory system,Disorder of skin,Exacerbation of multiple sclerosis (Acute),Hodgkin's disease,Inflammatory disorder of musculoskeletal system,Neoplastic disease,Nephrotic syndrome, Idiopathic or due to lupus erythematosus,Non-Hodgkin's lymphoma,Rheumatoid arthritis：5 to 60 mg/day ORALLY

Asthma
(moderate and severe exacerbation, 12years and younger) 1 to 2 mg/kg/day ORALLY in 2 divided doses (maximum 60 mg/day)
(long-term therapy, 11years and younger) 0.25 to 2 mg/kg ORALLY daily
(moderate and severe exacerbation, greater than age 12years) 40 to 80 mg/day ORALLY in 1 or 2 divided doses
(long-term therapy, 12years and older; ) 7.5 to 60 mg ORALLY daily

0.14-2ml/kg/day,TID~QID